GHENT, BELGIUM--(Marketwire - 03/15/10) - This announcement is an advertisement and not a prospectus. Investors should not subscribe for or purchase any securities referred to in this announcement except on the basis of information in the prospectus published by Ablynx NV (the “Company”) on 26 February 2010 (which is supplemented by an addendum approved by the CBFA on 7 March 2010) in connection with the Offering of offered shares and the admission of the new shares and VVPR strips to trading on Euronext Brussels (the “Prospectus”).
Ablynx, the biopharmaceutical company focused on the discovery and development of Nanobodies®, announced today that it has successfully completed its Secondary Public Offering (the “SPO” or “Offering”) raising EUR50 million.
The offered shares were priced at EUR7.5 per share. As a result of the Offering, 6,666,667 new shares, equivalent to EUR50 million, will be issued by Ablynx. Additionally, 400,000 over-allotment shares, equivalent to EUR3 million, will be allocated. The over-allotment shares are existing shares and if the over-allotment option is exercised in full, this will result in the sale of the over-allotment shares by the Lending Shareholders.
KBC Securities NV and UBS Investment Bank acted as Joint Global Coordinators and Joint Bookrunners, while Piper Jaffray Ltd. acted as Co-Manager to the Offering and while KBC Bank NV and Kempen & Co NV acted as selling agent.
Commenting on today’s announcement, Dr Edwin Moses, Ablynx’s Chairman and Chief Executive Officer said: “We are delighted to have successfully completed our secondary public offering and to have been able to attract a wide range of new specialist and generalist investors from Europe and the USA as well as receiving significant support from existing investors. I believe this is a reflection of the strength of our pipeline and our well validated Nanobody platform combined with the fact that we have delivered on all the promises we made at the IPO. We will now have increased flexibility to advance programmes through to clinical proof-of-concept, potentially commercialise our orphan drug programme, ALX- 0681, ourselves and/or co-invest in development alongside our pharmaceutical partners, in return for a greater share of the value we create. We believe all these activities will considerably enhance Ablynx’s future potential.”
For more information, please contact:
Contacts at Ablynx: Dr. Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com
Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com
Wim Ottevaere Chief Financial Officer t: +32 (0)9 262 00 08 e: wim.ottevaere@ablynx.com
For international media enquiries: College Hill Life Sciences Sue Charles, Justine Lamond t: +44 (0)20 7866 7857 e: ablynx@collegehill.com
